A small but growing body of research indicates that GLP-1 drugs, widely recognized for their effectiveness in treating obesity, may also prove beneficial in managing polyendocrine metabolic ovarian syndrome (PMOS), a hormonal disorder affecting approximately 1 in 8 women globally.
PMOS, previously known as polycystic ovary syndrome, is characterized by symptoms such as weight gain, irregular periods, and unwanted facial hair. For many, like 18-year-old Charlotte Touzalin, the condition has led to years of frustration and a difficult diagnostic journey. Touzalin shared her experience of struggling with weight and abnormal symptoms, mirroring those her mother, Anne Schultz, had faced for decades without a clear diagnosis.
"I didn’t understand why all this weight was coming back or why my friends didn’t have to shave their faces and I had to," Touzalin said. Her mother, Schultz, added, "We finally had an answer and some kind of a path for her."
Understanding PMOS
PMOS is a complex hormonal condition where two key hormones, insulin and testosterone, play significant roles. Most women with PMOS, regardless of body weight, experience insulin resistance, a condition where the body's cells do not respond effectively to insulin. This can lead to elevated insulin levels, which in turn can stimulate the ovaries to produce excess testosterone. This hormonal imbalance can result in symptoms like missed periods, severe acne, and excessive hair growth.
Diagnosis of PMOS can be challenging due to the wide variability of symptoms and their overlap with other medical conditions. The disorder often runs in families, and while many affected individuals are overweight, it is not a universal characteristic. Current management typically involves addressing symptoms through methods like birth control pills for period regulation and lifestyle adjustments for weight management.
Promising Results with GLP-1 Drugs
Recent studies are exploring the potential of GLP-1 drugs, such as semaglutide and exenatide, as a treatment for PMOS. In one study involving Touzalin, participants who received weekly semaglutide injections for 10 months experienced notable improvements. Touzalin reported slowed abnormal hair growth, normalized periods, and a reduction in constant weight gain. "I became a happier version of myself," she stated. "I felt like a normal person."
Early data from this study, published in the journal Fertility and Sterility, showed that eight out of eleven participants lost at least 10% of their body weight, with a median weight loss of approximately 42 pounds. Significant reductions in testosterone levels, with a median drop of 52%, were also observed. Additionally, six women experienced more regular periods, with four achieving monthly cycles.
Dr. Melanie Cree, who led several studies on GLP-1 drugs for PMOS, including the one Touzalin participated in, noted their effectiveness. "We are finding them incredibly effective and really exciting for improving symptoms in women with this condition," Dr. Cree said. Across three of her studies, women on GLP-1s consistently lost more weight and showed decreased levels of testosterone, blood sugar, and insulin compared to control groups.
Challenges and Future Directions
While research is ongoing and many doctors are prescribing GLP-1s off-label for PMOS, challenges remain. Insurance coverage is a significant hurdle, as these drugs are not yet FDA-approved for treating PMOS. This often leaves patients facing out-of-pocket expenses or struggling to obtain coverage. Touzalin herself recently had to stop taking the medication due to a lack of insurance coverage after completing her study participation.
Dr. Rana Malek, an endocrinologist at the University of Maryland Medical System, frequently prescribes these medications for patients with insulin resistance, particularly for weight management. She emphasized that while results can vary and side effects like nausea and constipation can occur, the drugs can offer substantial benefits for many PMOS patients. The frustration, she noted, stems from the insurance barriers preventing access.
Despite these challenges, the emerging research offers a renewed sense of hope for individuals and families affected by PMOS, pointing towards a potential new avenue for managing the complex hormonal disorder.